EPRX
$7.58
Pre-MarketAs of Mar 17, 8:00 PM UTC
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need.
Recent News
Eupraxia Reports Positive Six-Month Data From Eosinophilic Esophagitis Trial
Eupraxia Pharmaceuticals (EPRX.TO) Tuesday reported "positive data" from patients in the two highest
Eupraxia Pharmaceuticals Q4 Loss Widens
Eupraxia Pharmaceuticals (EPRX.TO) overnight Thursday reported a wider fourth-quarter net loss. T
Eupraxia Pharmaceuticals Closes US$63.2M Public Offering Including Full Exercise of Underwriter Option
Eupraxia Pharmaceuticals (EPRX.TO, EPRX) was at last look up 4% in late Friday afternoon trade in Ca
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering
Eupraxia Pharmaceuticals (EPRX.TO, EPRX) on Thursday announced the pricing of its previously announc
Here's Why We're Not At All Concerned With Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...